drugset / Trial / NCT04697719
Body Weight, Aspirin Dose and Pro-resolving Mediators
RandomizedCrossoverDouble-blindOther
Summary
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
Timeline
- Start
- 2021-11-04
- Primary completion
- 2025-01-29
- Completion
- 2025-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | Oral |
| Subject | Aspirin | Small molecule | 325 mg | Oral |
Indications
No indication recorded.